Healthcare
Live Price
Offline$4.40
+0.00% today
1Y Change
+35.38%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
WuXi Biologics (Cayman) Inc. (WXIBF) is a Healthcare stock with a market cap of $124.50B and listed on OTC. The stock last traded around $4.40 and up 35.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of +45.1%, a dividend yield of 0.0%. What stands out right now is revenue +13.7%, EPS +45.1%, free cash flow +117.4% with operating margin 30.5% and ROIC 9.2%. Valuation sits in the middle of the pack at P/E 24.6 and price/sales 5.8. Stock Foundry combines WXIBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WXIBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WXIBF Max Drawdown
-30.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WXIBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.3B
-32.6% YoY
FY Net Income
$3.4B
-23.3% YoY
Free Cash Flow
-$4.1B
-34.0% YoY
Revenue Growth
+13.7%
EPS Growth
+45.1%
Gross Margin
46.0%
Net Margin
22.5%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21.2B | 18.7B | 17.0B | 15.3B | 10.3B |
| Gross Profit | 9.8B | 7.7B | 6.8B | 6.7B | 4.8B |
| Operating Income | 6.5B | 5.0B | 4.5B | 4.3B | 3.2B |
| EBITDA | 8.2B | 6.4B | 5.5B | 6.2B | 4.5B |
| Net Income | 4.8B | 3.4B | 3.4B | 4.4B | 3.4B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.2B | 8.3B | 9.7B | 6.4B | 9.0B |
| Total Assets | 63.7B | 57.0B | 56.6B | 49.6B | 44.0B |
| Total Liabilities | 10.7B | 11.5B | 12.6B | 13.4B | 11.3B |
| Shareholder Equity | 47.3B | 41.8B | 40.3B | 35.0B | 32.3B |
| Total Debt | 3.1B | 4.9B | 4.6B | 4.4B | 4.3B |
| Net Debt | -6.1B | -3.3B | -5.1B | -2.0B | -4.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.9B
-45.2% YoY
Capital Expenditures
6.0B
+7.6% YoY
Free Cash Flow
4.1B
-34.0% YoY
Key ratios
Gross Margin
46.0%
Operating Margin
30.5%
Net Margin
22.5%
ROE
10.6%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.